01Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096. https://doi.org/10.1126/science.1258096
真实完整02董会芹, 纪林芹, 陈亮, 张文新 (2013). 3-5岁儿童对同伴侵害归因的特征研究. 心理发展与教育, 29(3), 225–231.
真实完整03Mnih, V., Kavukcuoglu, K., Silver, D., Graves, A., Antonoglou, I., Wierstra, D., & Riedmiller, M. (2013). Playing Atari with deep reinforcement learning. In NIPS Deep Learning Workshop.
会议名存疑The new frontier of genome engineering with CRISPR-Cas9
DOI: 10.1126/science.1258096
eISSN 1095-9203 · Publisher: American Association for the Advancement of Science
BACKGROUND: Technologies for making and manipulating DNA have enabled advances in biology ever since the discovery of the DNA double helix. But introducing site-specific modifications in the genomes of cells and organisms remained elusive. Early approaches relied on the principle of site-specific recognition of DNA sequences by oligonucleotides, small molecules, or self-splicing introns. More recently, the site-directed zinc finger nucleases (ZFNs) and TAL effector nucleases (TALENs) using the principles of DNA-protein recognition were developed. However, difficulties of protein design, synthesis, and validation remained a barrier to widespread adoption of these engineered nucleases for routine use.
ADVANCES: The field of biology is now experiencing a transformative phase with the advent of facile genome engineering in animals and plants using RNA-programmable CRISPR-Cas9. The CRISPR-Cas9 technology originates from type II CRISPR-Cas systems, which provide bacteria with adaptive immunity to viruses and plasmids. The CRISPR-associated protein Cas9 is an endonuclease that uses a guide sequence within an RNA duplex, tracrRNA:crRNA, to form base pairs with DNA target sequences, enabling Cas9 to introduce a site-specific double-strand break in the DNA. The dual tracrRNA:crRNA was engineered as a single guide RNA (sgRNA) that retains two critical features: a sequence at the 5′ side that determines the DNA target site by Watson-Crick base-pairing and a duplex RNA structure at the 3′ side that binds to Cas9. This finding created a simple two-component system in which changes in the guide sequence of the sgRNA program Cas9 to target any DNA sequence of interest. The simplicity of CRISPR-Cas9 programming, together with a unique DNA cleaving mechanism, the capacity for multiplexed target recognition, and the existence of many natural type II CRISPR-Cas system variants, has enabled remarkable developments using this cost-effective and easy-to-use technology to precisely and efficiently target, edit, modify, regulate, and mark genomic loci of a wide array of cells and organisms.
OUTLOOK: CRISPR-Cas9 has triggered a revolution in which laboratories around the world are using the technology for innovative applications in biology. This Review illustrates the power of the technology to systematically analyze gene functions in mammalian cells, study genomic rearrangements and the progression of cancers or other diseases, and potentially correct genetic mutations responsible for inherited disorders. CRISPR-Cas9 is having a major impact on functional genomics conducted in experimental systems. Its application in genome-wide studies will enable large-scale screening for drug targets and other phenotypes and will facilitate the generation of engineered animal models that will benefit pharmacological studies and the understanding of human diseases. CRISPR-Cas9 applications in plants and fungi also promise to change the pace and course of agricultural research. Future research directions to improve the technology will include engineering or identifying smaller Cas9 variants with distinct specificity that may be more amenable to delivery in human cells. Understanding the homology-directed repair mechanisms that follow Cas9-mediated DNA cleavage will enhance insertion of new or corrected sequences into genomes. The development of specific methods for efficient and safe delivery of Cas9 and its guide RNAs to cells and tissues will also be critical for applications of the technology in human gene therapy.
Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science, 346(6213), 1258096.
董会芹, 纪林芹, 陈亮, 张文新 (2013). 3-5岁儿童对同伴侵害归因的特征研究. 心理发展与教育, 29(3), 225–231.
He, K., Zhang, X., Ren, S., & Sun, J. (2016). Deep residual learning for image recognition. In Proceedings of the IEEE Conference on Computer Vision and Pattern Recognition (pp. 770–778).
彭聃龄 (2019). 普通心理学 (5版). 北京师范大学出版社.
Watson, J. D., & Crick, F. H. C. (1953). Molecular structure of nucleic acids: A structure for deoxyribose nucleic acid. Nature, 171(4356), 737–738. https://doi.org/10.1038/171737a0
类型
文件
本次核查共 32 条:待修正 22需核对 1未找到 5已验证 4
点击来源,核对记录的作者、刊名、卷期页码。
每一条结论,都有出处。
逐字段比对公开学术数据库:作者、标题、年份、卷期、页码、DOI等;每一条结论,点开出处即可复核。
先试后买,用多少买多少
每天 10 积分,每日重置。
复查窗口:3 天
一次性:30 / 100 / 300 / 800 积分
复查窗口:30 天
一季 / 一年 / 三年 可选
复查窗口:整个卡期
核验 1 积分 = 1 条;整理重排 1 积分 = 2 条;复查窗口内同条不重复计费。单次核验上限:免费 50 条,付费按档 100–600 条。复查窗口需注册后获得。
常见问题
「今日宜引文」有哪些功能?
「今日宜引文」提供两项功能:「引文核验」与「格式整理」。「格式整理」将参考文献整理为目标体例并支持导出,不对引文进行核验,不消耗积分。「核验」将引文逐条比对公开学术数据库;字段有出入的给出记录中的正确值,一键采用,缺的字段可补全;每条核验结果均附可点开的出处链接,未能找到的附通用手查链接。核完结果可换体例重排,导出干净参考文献列表。可同时导出详细的核验报告作为参考文献核验的记录。
核验是怎么进行的?
每条引文检索 CrossRef、OpenAlex、PubMed、Semantic Scholar、万方数据等权威学术数据库,必要时辅以网页检索,拿检索到的真实记录逐字段比对:作者、标题、年份、卷期、页码、DOI 等。中英文献可同批核验。判定基于比对结果,从严执行:不错放,不错怪。全程为确定性比对,没有大模型参与判定:同样的输入,永远得到同样的结论。
比对的数据库可信吗?
比对的都是公开学术索引:英文如 CrossRef、OpenAlex、PubMed,中文为万方数据与国家哲社文献中心等。命中的记录直接来自这些源,原样呈现;每条结论都附命中记录的链接,可自行点开核对。
准确率高吗?
核验将每一条引用学术数据库逐字段对比,判定依据是「数据库里是否存在相应条目」。只要文献被这些库收录,核验就非常「可靠」,每条核验结果都会附上来源链接,可逐条点开核实。真正的边界是收录范围,如较新的预印本、部分小众或地区性期刊、专著、个别字段等,可能未被公开数据库收录。这种情况下,我们会标注「未找到」并提供通用手查链接。
为什么判定不用 AI?
参考文献的核验是一个「检索—匹配」的过程,而非推理的过程。即使是当前最前沿的 AI 大模型也仍然会产生「幻觉」,它可能会给出看似可信但并不存在的文献信息,例如查无此项的 DOI,或对不上的作者、页码;用它来做判定,核验本身也可能跟着出错。所以判定层只用确定性的逐字段比对,不用 AI。每条结论都可复现,并附命中记录的链接,可逐条点开核对。
支持哪些体例和类型?
体例:GB/T 7714(2015 与 2025 两版,顺序编码制与著者—出版年制)、 APA 7、MLA 9、Chicago(第 18 版,著者-出版年)、IEEE、Vancouver;
文献类型:期刊、图书、会议论文、学位论文、报纸、预印本、数据集、地图、报告与政府文件。
当前支持的体例与文献类型可用全部功能(文献核验、格式处理、字段补全、体例转换等)。尚不支持的文献类型仅提供核验,不做字段补全与体例转换,条目原文保留。体例仅限定转换目标:以任何体例书写的引文都可核验,并可转换为受支持的体例。更多常用体例和文献类型会在后续版本逐步覆盖。
导入、导出支持哪些格式?
导入:可直接粘贴从文档里复制的参考文献,或以 .docx(Word)/ .bib(BibTeX)/ .ris(EndNote、Zotero、NoteExpress 等文献管理软件通用)/ .enw(EndNote)/ .txt 格式上传参考文献列表;导出:参考文献列表支持 .docx(Word)/ .txt / .pdf / .bib(BibTeX)/ .ris(可导回 EndNote、Zotero 等)格式导出;核验报告导出格式支持 .pdf / .docx / .md。
哪些场景用得上?
AI 辅助写作产生的参考文献,可引用前逐条核验。期刊投稿、开题报告与文献综述提交前及毕业论文与学位论文定稿前,都可使用「今日宜引文」来逐条核对引文与数据库记录是否一致,检查参考文献是否真实、完整、合乎体例,或按目标刊物要求转换格式。
怎么计费?
复查窗口是什么?
复查窗口从核查时起算,按档位:登录免费 3 天;按量包 30 天;通行卡为整个卡期。未注册用户无复查窗口。